KNX100 / Kinoxis Therapeutics  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
KNX100 / Kinoxis Therapeutics
ACTRN12624000747527: Study to Examine the Safety, Tolerability, and Efficacy of KNX100 in the Treatment of Subjects with Agitation Associated with Dementia

Not yet recruiting
2
60
 
Kinoxis Therapeutics Pty Ltd, Kinoxis Therapeutics Pty Ltd
Agitation in dementia
 
 

Download Options